References
- Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–787.
- Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015;6(13):1246–1258.
- Mayyas F, Alzoubi KH, Bonyan R. The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes. Cardiovasc Ther 2017;35(2):e12242.
- Silva MAB, Bruder-Nascimento T, Cau SBA, Lopes RAM, Mestriner FLAC, Fais RS, et al. Spironolcatone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015;6:269.
- Silva MA, Cau SB, Lopes RA, Manzato CP, Neves KB, Bruder-Nascimento T, et al. Mineralocorticoid receptor blockade prevents vascular remodeling in a rodent model of type 2 diabetes mellitus. Clin Sci (Lond.) 2015;129(7):533–545.
- Delcayre C. and Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999;43(1):7–12.
- Patel BM, Kakadiya J, Goyal RK, Mehta AA. Effect of Spironolactone on Cardiovascular Complications Associated with Type-2 Diabetes in Rats. Exp Clin Endocrinol Diabetes 2013;121:441–447.
- Garg R, Rao AD, Baimas-George M, Hurwitz S, Foster C, Shah RV, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015;64(1):236–42.
- Vranic A, Simovic S, Ristic P, Nikolic T, Stojic I, Srejovic I, et al.. The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2017;95(11):1343–1350.
- Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the reninangiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773–3780.
- Toda N, Nakanishi S, Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol 2013;168:519–533.
- Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004;65:1435–1439.
- Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol 2018;123(3):233–235.
- Pick E, Keisari Y. A simple colometric method for the measurement of hydrogen peroxide by cells in culture. J Immunol Methods 1980;38:161–170.
- Green LC, Wagner DA, Glogowski J, Skipper PI, Wishnok JS, Tannenbaum SR Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal Biochem 1982;126:131–138.
- Auclair C, Voisin E. Nitroblue Tetrazolium reduction. In: Greenwald RA (ed) Handbook of methods for oxygen radical research. CRP Press, Boca Raton, 1985. pp 123–132.
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–358.
- Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment Clinical Science 2004;107:539–557.
- Li YW, Aeno WS. Diabetes Mellitus and Cardiovascular Disease. J Clinic Experiment Cardiol 2011;2:114.
- Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602.
- Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive - diabetic heart disease. Circulation 1990;82:848–85.
- Poornima IG, Parkih P, Shanon RP. Diabetic Cardiomyopathy: search for unifying hypoyhesis Circ Res 2006;98:596–605.
- Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, et al. Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy. Curr Cardiol Rev 2010;6:280–290.
- Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular Endocrinol 2006;20:953–970.
- Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A. et al. Myocardial cell death in human diabetes. Circ Res 2000;87:1123–1132.
- Robert V, Heymes C, Silvestre JS. Angiotensin AT1receptor subtype as a cardiac target of aldosterone: role in aldosterone salt induced fibrosis. Hypertension 1999;33:981–986.
- Nagatomo Y, Meguro T, Ito H, Koide K, Anzai T, Fukuda K. et al. Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy. PLoS One 2014;9(3):e93145.
- Verma S, Violet GY, Badiwala M, Anderson JT, McNiel LH. Working heart function in diabetes is not improved by spironolactone treatment Can J Physiol Pharmacol 2003;81:493–496.
- Ojeda-Cervantes M, Barrera-Chimal J, Alberú J, Pérez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. Am J Nephrol 2013;37(5):481–90.
- Silva MA, Bruder-Nascimento T, Cau SB, Lopes RA, Mestriner FL, Fais RS, Touyz, RM, Tostes RC. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015;6:269.
- Kosugi T, Heining M, Nakayama T, Matsuo S, Nakagawa T. eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists. Am J Path 2010;176(2):619–629.
- Hayashi T, Shibata H, Kurihara I, Yokota K, Mitsuishi Y, Ohashi, K, et al. High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling. Int Heart J 2017;58:794–802.
- Barbato JC, Mulrow PJ, Shapiro JI and Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 2002;40(2):130–135.
- Haas MJ, Jurado-Flores M, Hammoud R, Feng V, Gonzales K, Onstead-Haas L, Mooradian AD. The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion from Human Coronary Artery Endothelial Cells. Am J Therapeut 2019;26(3):e321–e332.
- Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008;14:1370–1376.
- Kawakami-Moori F and Shimosawa T. Oxidative Stress and Mineralocorticoid Receptor Signaling in the Brain: Possible Therapeutic Targets for Dementia. Ann Clin Exp Hypertesion 2012;2(2):1015–1020.